

# Andrey Soares

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9565656/publications.pdf>

Version: 2024-02-01

19  
papers

163  
citations

1307366

7  
h-index

1199470

12  
g-index

19  
all docs

19  
docs citations

19  
times ranked

316  
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2022, 18, 1185-1198.	1.1	10
2	Clinicopathological characterization, FGFR alteration prevalence, and outcomes of locally advanced or metastatic urothelial cancer in Latin America (LACOG 1518).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16549-e16549.	0.8	2
3	Health-related quality-of-life (HRQoL) analysis from a randomized phase II trial of androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.. <i>Journal of Clinical Oncology</i> , 2021, 39, 64-64.	0.8	0
4	Clinical-pathological characterization and outcomes of metastatic urothelial cancer in Latin America: Retrospective and translational multicenter database (LACOG 1518).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS497-TPS497.	0.8	0
5	Consensus on Treatment and Follow-Up for Biochemical Recurrence in Castration-Sensitive Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries. <i>JCO Global Oncology</i> , 2021, 7, 538-544.	0.8	2
6	Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCDC). <i>JCO Global Oncology</i> , 2021, 7, 559-571.	0.8	10
7	Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries. <i>JCO Global Oncology</i> , 2021, 7, 545-549.	0.8	3
8	PBRM1 Mutations as a Predictive Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2021, 5, 79-92.	0.2	2
9	A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG) Tj ETQq1 1 0.384314 egBT /Ov		
10	Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice. <i>Oncology</i> , 2020, 98, 1-9.	0.9	10
11	Penile cancer: a Brazilian consensus statement for low- and middle-income countries. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3281-3296.	1.2	9
12	Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1829-1845.	1.2	3
13	First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 244-251.e4.	0.9	16
14	Impact of the COVID-19 Pandemic on the Urologist's clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 501-510.	0.7	59
15	Alternative Therapies to Bacillus Calmette-Guérin Shortage for Nonmuscle Invasive Bladder Cancer in Brazil and Other Underdeveloped Countries: Management Considerations. <i>Journal of Global Oncology</i> , 2019, 5, 1-9.	0.5	7
16	Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721987232.	0.9	3
17	Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4579-4579.	0.8	1
18	Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: Consensus opinion from a panel of experts. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 30-34.	2.0	12

#	ARTICLE	IF	CITATIONS
19	Applications for a hybrid operating room in thoracic surgery: from multidisciplinary procedures to image-guided video-assisted thoracoscopic surgery. <i>Jornal Brasileiro De Pneumologia</i> , 2016, 42, 387-390.	0.4	6